Ensiklopedia Dunia

Ergotamin
Data klinis
Nama dagang	Cafergot (with caffeine), Ergomar, others
Nama lain	2'-Methyl-5'α-benzyl-12'-hydroxy-3',6',18-trioxoergotaman; 9,10α-Dihydro-12'-hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3',6',18-trione
AHFS/Drugs.com	monograph
Rute; pemberian	Oral
Kode ATC	N02CA02 (WHO) ;
Status hukum
Status hukum	AU: S4 (Prescription only) ; CA: Schedule VI ; UK: POM (Hanya resep) ; US: ℞-only DEA controlled precursor;
Data farmakokinetika
Bioavailabilitas	Intravenous: 100%, ; Intramuscular: 47%,; Oral: <1% (Enhanced by co-administration of caffeine)
Metabolisme	Hepatic
Waktu paruh eliminasi	2 hours
Ekskresi	90% biliary
Pengenal
	Nama IUPAC (6aR,9R)-N-((2R,5S,10aS,10bS)-5-Benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide;
Nomor CAS	113-15-5 ;
PubChem CID	8223;
IUPHAR/BPS	149;
DrugBank	DB00696 ;
ChemSpider	7930 ;
UNII	PR834Q503T;
KEGG	D07906 ;
ChEBI	CHEBI:64318 ;
ChEMBL	ChEMBL442 ;
Ligan PDB	ERM (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID9043774 ;
ECHA InfoCard	100.003.658
Data sifat kimia dan fisik
Rumus	C33H35N5O5
Massa molar	581,67 g·mol−1
Model 3D (JSmol)	Gambar interaktif;
	SMILES C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;
	InChI InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1 ; Key:XCGSFFUVFURLIX-VFGNJEKYSA-N ;
	(what is this?) (verify)

Ergotamin adalah obat yang digunakan untuk meredakan atau mencegah migrain. Obat ergotamin biasanya dapat ditemukan dalam produk obat yang dikombinasikan dengan kafein. Obat ergotamin merupakan vasokonstriktor agonis adrenergik selektif alfa-1.^[4]^[5]

Referensi

^ ^a ^b Sanders SW, Haering N, Mosberg H, Jaeger H (1986). "Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing". European Journal of Clinical Pharmacology. 30 (3): 331–334. doi:10.1007/BF00541538. PMID 3732370. S2CID 37538721.
^ ^a ^b ^c ^d Tfelt-Hansen P, Johnson ES (1993). "Ergotamine". Dalam Olesen J, Tfelt-Hansen P, Welch KM (ed.). The Headaches. New York: Raven Press. hlm. 313–22.
^ Ibraheem JJ, Paalzow L, Tfelt-Hansen P (December 1983). "Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers". British Journal of Clinical Pharmacology. 16 (6): 695–699. doi:10.1111/j.1365-2125.1983.tb02243.x. PMC 1428366. PMID 6419759.
^ "Ergotamine-Caffeine Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD". www.webmd.com (dalam bahasa Inggris). Diakses tanggal 2023-06-20.
^ "Ergotamine". go.drugbank.com. Diakses tanggal 2023-06-20.

Artikel bertopik farmasi ini adalah sebuah rintisan. Anda dapat membantu Wikipedia dengan mengembangkannya.

[kinetics1-1] Sanders SW, Haering N, Mosberg H, Jaeger H (1986). "Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing". European Journal of Clinical Pharmacology. 30 (3): 331–334. doi:10.1007/BF00541538. PMID 3732370. S2CID 37538721.

[kinetics2-2] Tfelt-Hansen P, Johnson ES (1993). "Ergotamine". Dalam Olesen J, Tfelt-Hansen P, Welch KM (ed.). The Headaches. New York: Raven Press. hlm. 313–22.

[pmid6419759-3] Ibraheem JJ, Paalzow L, Tfelt-Hansen P (December 1983). "Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers". British Journal of Clinical Pharmacology. 16 (6): 695–699. doi:10.1111/j.1365-2125.1983.tb02243.x. PMC 1428366. PMID 6419759.

[4] "Ergotamine-Caffeine Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD". www.webmd.com (dalam bahasa Inggris). Diakses tanggal 2023-06-20.

[5] "Ergotamine". go.drugbank.com. Diakses tanggal 2023-06-20.

[1]

[2]

[3]

[4]

[5]

Ensiklopedia Dunia

Ergotamin

Referensi

Beranda

Program Studi